key: cord-0731897-rmv5otwr
authors: Li, Wenjuan; Li, Xingxing; Zhao, Danhua; Liu, Jingjing; Wang, Ling; Li, Miao; Liu, Xinyu; Li, Jia; Wu, Xiaohong; Li, Yuhua
title: Heterologous prime-boost with AdC68- and mRNA-based COVID-19 vaccines elicit potent immune responses in mice
date: 2021-12-13
journal: Signal Transduct Target Ther
DOI: 10.1038/s41392-021-00843-6
sha: fb2a63788c2ba4c66516fcc98fd18f0065378312
doc_id: 731897
cord_uid: rmv5otwr

nan

groups i.m.ARCoV>i.n.ChAd and i.m.ARCoV>i.m.ChAd) had stronger neutralizing responses than groups 1×i.n.ChAd, 2×i.n.ChAd, 1×i.m.ChAd, 2×i.m.ChAd, and 1×i.m.ARCoV. Homologous ChAdTS-S boost (i.n. or i.m.) did not significantly elevate the neutralizing response. The NAb GMTs of i.n.ChAdTS-S immunization groups (422 for group 1×i.n.ChAd and 571 for group 2×i.n. ChAd) were higher than those of i.m.ChAdTS-S immunization groups (193 for group 1×i.m.ChAdT and 146 for group 2×i.m. ChAd). However, there were no significant statistical differences among these four groups.

The mucosal immunity level was assessed by detecting the spike-specific IgA titers in the serum using ELISA on day 35 after the prime immunization (Fig. 1d ). All the groups administered at least one dose of i.n.ChAd (i.n.ChAd>i.m.ARCoV, i.m.ARCoV>i.n. ChAd, 1×i.n.ChAd, and 2×i.n.ChAd) exhibited high spike-specific IgA titers with no significant differences, indicating high mucosal immunity levels. Groups i.m.ARCoV>i.n.ChAd and 2×i.n.ChAd had the highest IgA GMTs. The second dose of i.n.ChAdTS-S boost did not significantly elevate the mucosal immunity level. The other groups administered without i.n.ChAd (i.m.ChAd>i.m.ARCoV, i.m. ARCoV>i.m.ChAd, 1×i.m.ChAd, 2×i.m.ChAd, 1×i.m.ARCoV, 2×i.m. ARCoV, i.n.Blank, and i.m.Blank) did not elicit significant mucosal immune responses.

To investigate the spike-specific T cell responses on day 56 after prime immunization, splenic lymphocytes were stimulated for 24 h with peptide pools (15mers with 11 aa overlap), spanning the entire SARS-CoV-2 spike protein, and IFN-γ ELISpot assay was conducted. The results ( Few studies have reported the longevity of high antibody titers induced by heterologous prime-boost vaccination regimens. We detected serum spike-specific IgG, NAb, and IgA titers following ChAdTS-S and ARCoV heterologous prime-boost in mice for 112 days after the prime vaccination. In all the immunized groups, spikespecific IgG levels (Fig. 1f, Supplementary Figs . S1-S12) and VSVbased pseudovirus NAb GMTs (Fig. 1g, Supplementary Figs . S13-S24) peaked at day 28 after the prime vaccination (7 days after the boost) and were maintained until day 112. The spike-specific IgA titers of the groups i.n.ChAd>i.m.ARCoV, 1×i.n.ChAd, and 2×i.n.ChAd were high and similar on day 14 post-prime vaccination, rising to a peak on day 28 (7 days after the boost), and lasted until day 112 (Fig. 1h, Supplementary Figs. S25, S29, and S30) . The spike-specific IgA titers of the group i.m.ARCoV>i.n.ChAd were as high as those of the blank groups on day 14, increased significantly to the same peak level as those of group i.n.ChAd>i.m.ARCoV on day 28, and lasted until day 112 (Fig. 1h, Supplementary Fig. S26 ARCoV, i.n.Blank, and i.m.Blank) remained negative throughout the 112 days after the prime vaccination (Fig. 1h, Supplementary Figs . S27, S28, S31-S36).

In our investigation, the ChAdTS-S intranasally immunized heterologous prime-boost group (i.n.ChAd>i.m.ARCoV) had not only high neutralizing ability and systemic immune responses, but also a strong mucosal immune response and a strongT cell immunity. It may be a promising method to protect the population against SARS-CoV-2 infection. First, the i.n.ChAdTS-S priming delivered antigens to the site of infection. It initiated high mucosal immunity in the respiratory tract with systemic humoral and cellular immunity, achieving rapid and comprehensive protection. Intranasal immunization is non-invasive and easy to administer. For children who are afraid of needles, this route is more acceptable. Next, the i.m.ARCoV boosting significantly increased the IgG and NAb titers to the level as high as that elicited by 2×ARCoV. When faced with supply shortages of COVID-19 vaccines, governments can distribute new vaccines immediately without worrying about setting aside a second dose of a specific vaccine to inoculate people weeks or months later.

There are certain limitations of this investigation. First, only one group of mice of a specific age and gender were used; hence, the implications of the heterologous prime-boost strategy based on age, gender, and mice type have not been discussed. Further studies are needed to evaluate these factors. Next, the neutralizing capacities against SARS-CoV-2 variants, such as B.1.1.7 (Alpha), B.1.351 (Beta) and B.1.617.2 (Delta), were not determined after the ChAdTS-S and ARCoV heterologous prime-boost. We are working to obtain pseudovirus or live virus samples of these variants to overcome this limitation.

In conclusion, our research showed that heterologous primeboost with ChAdTS-S and ARCoV could induce a significantly strong immune response, thereby providing reference data for optimization of vaccination programs for COVID-19 vaccines.

The original datasets are available from the corresponding author upon request.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. indicates vaccination, 5 × 10 9 VP of ChAdTS-S or 6 μg of ARCoV were used for each vaccination.

indicates blood sample collection. indicates splenic lymphocyte isolation. i.n. indicates intranasal vaccination. i.m. indicates intramuscular vaccination. − indicates no boost vaccination. b-d The serum spike-specific binding IgG titers (b), pseudovirus NAb titers (c), and spike-specific binding IgA titers (d) on day 35 after prime immunization (N = 7-10 per group). e T cell response to SARS-CoV-2 spike peptides measured using an IFN-γ ELISpot on day 56 after the prime immunization (N = 5 per group). f-h Temporal changes in the serum spike-specific IgG titers (f), pseudovirus NAb titers (g), and spike-specific IgA titers (h) for up to 112 days after the prime immunization (N = 5-6 per group). In the VSV-based pseudovirus assay, NAb titers less than 30 were recorded as 30 when plotting the figures. Bars represent the geometric means with geometric SDs, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns: p > 0.05. SFU spot forming unit

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Single-dose immunization with a chimpanzee adenovirus-based vaccine induces sustained and protective immunity against SARS-CoV-2 infection

A thermostable mRNA vaccine against COVID-19

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

We sincerely thank Walvax Biotechnology Co., Ltd. and Suzhou Abogen Biosciences Co., Ltd. for providing the ChAdTS-S and ARCoV vaccine samples. We appreciate the technical support extended by Professor Linqi Zhang at School of Medicine, Tsinghua University. We extend our regards to Professor Weijin Huang at Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, the National Institutes for Food and Drug Control for providing the VSV-based pseudoviruses and technical support. We appreciate Dr. Lihong Yang, Shouchun Cao and Miao Xu in the National Institutes for Food and Drug Control for material and administrative support.